Pub. Date : 2016 Dec
PMID : 27748803
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | However, the function of Bcl-2 in cisplatin resistance in human ovarian cancer cells is not fully understood. | Cisplatin | BCL2 apoptosis regulator | Homo sapiens |
| 2 | In this study, we found that the pharmacological inhibitor ABT737 or genetic knockdown of Bcl-2 increased cisplatin cytotoxicity in cisplatin-resistant ovarian cancer cells. | Cisplatin | BCL2 apoptosis regulator | Homo sapiens |
| 3 | In this study, we found that the pharmacological inhibitor ABT737 or genetic knockdown of Bcl-2 increased cisplatin cytotoxicity in cisplatin-resistant ovarian cancer cells. | Cisplatin | BCL2 apoptosis regulator | Homo sapiens |
| 4 | Additionally, treatment with ABT737 or Bcl-2 siRNA increased cisplatin-induced free Ca2+ levels in the cytosol and mitochondria, which increased endoplasmic reticulum (ER)-associated and mitochondria-mediated apoptosis. | Cisplatin | BCL2 apoptosis regulator | Homo sapiens |
| 5 | In addition, ABT737 or Bcl-2 siRNA increased the ER-mitochondria contact sites induced by cisplatin in cisplatin-resistant SKOV3/DDP ovarian cancer cells. | Cisplatin | BCL2 apoptosis regulator | Homo sapiens |
| 6 | In addition, ABT737 or Bcl-2 siRNA increased the ER-mitochondria contact sites induced by cisplatin in cisplatin-resistant SKOV3/DDP ovarian cancer cells. | Cisplatin | BCL2 apoptosis regulator | Homo sapiens |
| 7 | Collectively, these results indicate that pharmacological inhibitors or genetic knockdown of Bcl-2 may be a potential strategy for improving cisplatin treatment of ovarian cancer. | Cisplatin | BCL2 apoptosis regulator | Homo sapiens |